Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. MediWound Ltd.
  6. News
  7. Summary
    MDWD   IL0011316309

MEDIWOUND LTD.

(MDWD)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

MediWound to Report Third Quarter 2021 Financial Results and Host a Conference Call and Webcast on November 16, 2021

11/04/2021 | 07:01am EST

YAVNE, Israel, Nov. 04, 2021 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation bio-therapeutic solutions for tissue repair and regeneration, today announced that the Company will release its financial results for the third quarter ended September 30, 2021 at 7:00 am Eastern Time on Tuesday, November 16, 2021.

Following the release, MediWound's management will host a conference call and live webcast on Tuesday, November 16, 2021 at 8:30 am Eastern Time to discuss the financial results and to answer questions. Dial-in and call details are as follows: 

Conference Call & Webcast Details
Toll-Free:877-602-7189
Israel:1-809-315-362
International:678-894-3057
Conference ID:7771457
Webcast:https://edge.media-server.com/mmc/p/2e5hd5wu

To access the call, participants should dial the applicable telephone number above at least 5 minutes prior to the start of the call.  An archived version of the webcast will be available for replay for 90 days in the Investors section of the MediWound website.

About MediWound Ltd.
MediWound is a biopharmaceutical company that develops, manufactures and commercializes novel, cost effective, bio-therapeutic solutions for tissue repair and regeneration. Our strategy leverages our enzymatic technology platform, focused on next-generation bioactive therapies for burn, wound care and tissue repair. NexoBrid®, our commercial orphan biological product for non-surgical eschar removal of deep, partial and full-thickness thermal burns, is a bromelain-based biological product containing a sterile mixture of proteolytic enzymes that selectively removes burn eschar within four hours without harming surrounding viable tissue. NexoBrid is currently marketed in the European Union and other international markets and is at registration-stage in the U.S. NexoBrid is supported by the U.S. Biomedical Advanced Research and Development Authority (BARDA).

EscharEx, our next-generation bioactive therapy for debridement of chronic and hard-to-heal wounds, is a product candidate in advanced stages of development. In two Phase 2 studies, EscharEx was well-tolerated and has demonstrated safety and efficacy in the debridement of various chronic and other hard-to-heal wounds, within a few daily applications.

MW005, is a topical biological drug for the treatment of non-melanoma skin cancers, is a clinical-stage product candidate under development.

Committed to innovation, we are dedicated to improving quality of care and patient lives. For more information, please visit www.mediwound.com.

Contacts:
Boaz Gur-Lavie Monique Kosse
Chief Financial OfficerManaging Director, LifeSci Advisors
MediWound Ltd. 212-915-3820
ir@mediwound.commonique@lifesciadvisors.com

All news about MEDIWOUND LTD.
2021MediWound Says Phase 2 Study of EscharEx Treatment for Chronic Wounds Delivers Positive..
MT
2021MEDIWOUND : Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of Es..
PU
2021MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of E..
AQ
2021MediWound Announces Positive Initial Data from its U.S. Phase 2 Pharmacology Study of E..
CI
2021MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study, Topl..
AQ
2021MediWound Completes Enrollment of Phase 2 Study of EscharEx; Shares Rise Pre-Bell
MT
2021MEDIWOUND : Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study - Form..
PU
2021MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
AQ
2021MediWound Completes Enrollment of its EscharEx U.S. Phase 2 Adaptive Design Study
CI
2021EMA Provides Regulatory Path for Pediatric Label Extension for NexoBrid
GL
More news
Analyst Recommendations on MEDIWOUND LTD.
More recommendations
Financials (USD)
Sales 2021 23,8 M - -
Net income 2021 -13,4 M - -
Net Debt 2021 - - -
P/E ratio 2021 -4,96x
Yield 2021 -
Capitalization 66,2 M 66,2 M -
Capi. / Sales 2021 2,78x
Capi. / Sales 2022 2,60x
Nbr of Employees -
Free-Float 57,2%
Chart MEDIWOUND LTD.
Duration : Period :
MediWound Ltd. Technical Analysis Chart | MDWD | IL0011316309 | MarketScreener
Technical analysis trends MEDIWOUND LTD.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 2,43 $
Average target price 6,92 $
Spread / Average Target 185%
EPS Revisions
Managers and Directors
Sharon Malka Chief Executive Officer
Boaz Gur-Lavie Chief Financial Officer
Stephen T. Wills Executive Chairman
Lior Rosenberg Chief Medical Officer
Ety Klinger Chief Research & Development Officer
Sector and Competitors
1st jan.Capi. (M$)
MEDIWOUND LTD.2.97%66
CSL LIMITED-9.01%91 245
WUXI BIOLOGICS (CAYMAN) INC.-3.19%48 492
SAMSUNG BIOLOGICS CO.,LTD.-9.41%45 433
ALEXION PHARMACEUTICALS, INC.0.00%40 336
BIOGEN INC.-8.09%32 393